$PROK
PROKIDNEY CORP. Stock $prok

$prok Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000095017024034946 Filed on March 22, 2024

Income Statement

Concept	2023 Q4	2023	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.682M	$44.82M	$70.94M
YoY Change	-82.0%	-36.82%	701.1%
% of Gross Profit
Research & Development	$22.53M	$106.7M	$82.07M
YoY Change	7.84%	30.02%	77.43%
% of Gross Profit
Depreciation & Amortization	$1.143M	$3.853M	$3.036M
YoY Change	44.5%	26.91%	53.02%
% of Gross Profit
Operating Expenses	$24.21M	$151.5M	$153.0M
YoY Change	-19.93%	-0.97%	6458.52%
Operating Profit		-$151.5M	-$153.0M
YoY Change		-0.97%	177.64%
Interest Expense	$5.277M	$12.00K	$215.0K
YoY Change	19.93%	-94.42%	2484.13%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$18.93M	-$129.5M	-$147.2M
YoY Change	-26.72%	-12.08%	6233.87%
Income Tax	$2.791M	$5.996M	$896.0K
% Of Pretax Income
Net Earnings	-$5.701M	-$35.47M	-$148.1M
YoY Change	-12.12%	-76.06%	6272.41%
Net Earnings / Revenue
Basic Earnings Per Share			-$0.23
Diluted Earnings Per Share	-$0.09	-$0.57	-$0.23
COMMON SHARES
Basic Shares Outstanding			61.54M
Diluted Shares Outstanding			61.54M

Balance Sheet

Concept	2023 Q4	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$363.0M	$363.0M	$490.3M
YoY Change	-25.97%	-25.97%	111196.96%
Cash & Equivalents	$60.65M	$60.65M	$490.3M
Short-Term Investments	$302.3M	$302.3M
Other Short-Term Assets	$9.000K	$9.821M	$14.47M
YoY Change	-99.35%	-32.11%	2769.35%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$374.1M	$374.1M	$504.7M
YoY Change	-25.87%	-25.87%	53327.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$42.14M	$46.41M	$13.06M
YoY Change	293.57%	255.22%	3.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$46.41M	$46.41M	$13.28M
YoY Change	249.52%	249.52%	-94.69%
TOTAL ASSETS
Total Short-Term Assets	$374.1M	$374.1M	$504.7M
Total Long-Term Assets	$46.41M	$46.41M	$13.28M
Total Assets	$420.6M	$420.6M	$518.0M
YoY Change	-18.81%	-18.81%	106.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.098M	$5.098M	$3.044M
YoY Change	67.48%	67.48%	60780.0%
Accrued Expenses	$17.67M	$18.42M	$7.794M
YoY Change	140.8%	136.28%	317.95%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$52.00K	$52.00K	$35.00K
YoY Change	48.57%	48.57%	-85.11%
Total Short-Term Liabilities	$25.04M	$25.04M	$10.87M
YoY Change	130.28%	130.28%	478.41%
LONG-TERM LIABILITIES
Long-Term Debt	$104.0K	$104.0K	$48.00K
YoY Change	116.67%	116.67%
Other Long-Term Liabilities	$4.074M	$4.074M	$2.136M
YoY Change	90.73%	90.73%	-72.26%
Total Long-Term Liabilities	$4.178M	$4.178M	$2.184M
YoY Change	91.3%	91.3%	-71.64%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.04M	$25.04M	$10.87M
Total Long-Term Liabilities	$4.178M	$4.178M	$2.184M
Total Liabilities	$29.22M	$1.524B	$1.615B
YoY Change	123.76%	-5.62%	16754.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.140B
YoY Change	3.22%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.103B	-$1.103B	-$1.097B
YoY Change
Total Liabilities & Shareholders Equity	$420.6M	$420.6M	$518.0M
YoY Change	-18.81%	-18.81%	106.21%

Cashflow Statement

Concept	2023 Q4	2023	2022
OPERATING ACTIVITIES
Net Income	-$5.701M	-$35.47M	-$148.1M
YoY Change	-12.12%	-76.06%	6272.41%
Depreciation, Depletion And Amortization	$1.143M	$3.853M	$3.036M
YoY Change	44.5%	26.91%	53.02%
Cash From Operating Activities	-$25.38M	-$90.07M	-$77.09M
YoY Change	61.02%	16.84%	6271.78%
INVESTING ACTIVITIES
Capital Expenditures	$1.567M	$34.20M	$1.846M
YoY Change	412.09%	1752.49%	-64.45%
Acquisitions
YoY Change
Other Investing Activities	-$94.28M	-$295.8M	$108.0K
YoY Change		-273975.93%	-100.04%
Cash From Investing Activities	-$95.84M	-$330.0M	-$1.738M
YoY Change	31221.24%	18886.36%	-99.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$9.499M	$542.5M
YoY Change		-98.25%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-9.511M	-9.551M	548.5M
YoY Change	118787.5%	-101.74%	117.97%
NET CHANGE
Cash From Operating Activities	-25.38M	-90.07M	-77.09M
Cash From Investing Activities	-95.84M	-330.0M	-1.738M
Cash From Financing Activities	-9.511M	-9.551M	548.5M
Net Change In Cash	-130.7M	-429.6M	469.7M
YoY Change	713.27%	-191.46%	106532.31%
FREE CASH FLOW
Cash From Operating Activities	-$25.38M	-$90.07M	-$77.09M
Capital Expenditures	$1.567M	$34.20M	$1.846M
Free Cash Flow	-$26.95M	-$124.3M	-$78.94M
YoY Change	67.71%	57.43%	1133.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001850270
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#RightOfUseAssetsOperatingAndFinanceLease
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#RightOfUseAssetsOperatingAndFinanceLease
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#OperatingAndFinanceLeaseLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#OperatingAndFinanceLeaseLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#RightOfUseAssetsOperatingAndFinanceLease
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#RightOfUseAssetsOperatingAndFinanceLease
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#OperatingAndFinanceLeaseLiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#OperatingAndFinanceLeaseLiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://www.prokidney.com/20231231#OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40560
CY2023	dei	Entity Registrant Name EntityRegistrantName	ProKidney Corp
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1586514
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2000 Frontis Plaza Blvd
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 250
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Winston-Salem
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27103
CY2023	dei	City Area Code CityAreaCode	336
CY2023	dei	Local Phone Number LocalPhoneNumber	999-7028
CY2023	dei	Security12b Title Security12bTitle	Class A ordinary shares, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	PROK
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	688858985
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Raleigh, North Carolina, United States
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60649000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	490252000
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	302301000
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	0
CY2023Q4	us-gaap	Interest Receivable InterestReceivable	1375000
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	0
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3399000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2624000
CY2023Q4	prok	Prepaid Clinical Current PrepaidClinicalCurrent	6413000
CY2022Q4	prok	Prepaid Clinical Current PrepaidClinicalCurrent	10459000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	9000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1384000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	374146000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	504719000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42143000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10708000
CY2023Q4	prok	Right Of Use Assets Operating And Finance Lease RightOfUseAssetsOperatingAndFinanceLease	4263000
CY2022Q4	prok	Right Of Use Assets Operating And Finance Lease RightOfUseAssetsOperatingAndFinanceLease	2356000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	213000
CY2023Q4	us-gaap	Assets Assets	420552000
CY2022Q4	us-gaap	Assets Assets	517996000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5098000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3044000
CY2023Q4	prok	Operating And Finance Lease Liabilities Current OperatingAndFinanceLeaseLiabilitiesCurrent	803000
CY2022Q4	prok	Operating And Finance Lease Liabilities Current OperatingAndFinanceLeaseLiabilitiesCurrent	493000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17665000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7336000
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1472000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25038000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10873000
CY2023Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	568000
CY2022Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	278000
CY2023Q4	prok	Operating And Finance Lease Liabilities Non Current Portion OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion	3610000
CY2022Q4	prok	Operating And Finance Lease Liabilities Non Current Portion OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion	1906000
CY2023Q4	us-gaap	Liabilities Liabilities	29216000
CY2022Q4	us-gaap	Liabilities Liabilities	13057000
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	1494732000
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	1601555000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	36114000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	7476000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	130000
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-134950000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-148135000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-55146000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1139663000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1104116000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1103396000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1096616000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	420552000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	517996000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	106707000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	82070000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46255000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44815000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	70937000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8855000
CY2023	us-gaap	Operating Expenses OperatingExpenses	151522000
CY2022	us-gaap	Operating Expenses OperatingExpenses	153007000
CY2021	us-gaap	Operating Expenses OperatingExpenses	55110000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-151522000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-153007000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-55110000
CY2023	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	22083000
CY2022	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	5983000
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2000
CY2023	us-gaap	Interest Expense InterestExpense	12000
CY2022	us-gaap	Interest Expense InterestExpense	-215000
CY2021	us-gaap	Interest Expense InterestExpense	0
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-129451000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-147239000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55108000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5996000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	896000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38000
CY2023	us-gaap	Profit Loss ProfitLoss	-135447000
CY2022	us-gaap	Profit Loss ProfitLoss	-148135000
CY2021	us-gaap	Profit Loss ProfitLoss	-55146000
CY2023	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-99979000
CY2022	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	-40103000
CY2021	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0
CY2023	us-gaap	Profit Loss ProfitLoss	-135447000
CY2022	us-gaap	Profit Loss ProfitLoss	-148135000
CY2021	us-gaap	Profit Loss ProfitLoss	-55146000
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	497000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	497000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-99612000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-40103000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35338000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-108032000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55146000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	9864000
CY2021	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	71500000
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	699000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55146000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26917000
CY2022	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	6050000
CY2022	prok	Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Value Prior To Business Combination AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValuePriorToBusinessCombination	63667000
CY2022	prok	Net Loss Prior To The Business Combination NetLossPriorToTheBusinessCombination	-93632000
CY2022	prok	Effect Of Business Combination During Period Value EffectOfBusinessCombinationDuringPeriodValue	-1092694000
CY2022	prok	Equity Based Compensation After The Business Combination1 EquityBasedCompensationAfterTheBusinessCombination1	7155000
CY2022	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	321000
CY2022	prok	Net Loss After The Business Combination NetLossAfterTheBusinessCombination	-14400000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1096616000
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	23841000
CY2023	prok	Exchange Of Class B Ordinary Shares Amount ExchangeOfClassBOrdinarySharesAmount	9500000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	9499000
CY2023	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	4795000
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	130000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35468000
CY2023	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-79000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1103396000
CY2023	us-gaap	Profit Loss ProfitLoss	-135447000
CY2022	us-gaap	Profit Loss ProfitLoss	-148135000
CY2021	us-gaap	Profit Loss ProfitLoss	-55146000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3853000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3036000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1984000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	30846000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	74469000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	699000
CY2023	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	6018000
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	0
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-23000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	1375000
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4648000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7231000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5704000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	11639000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	494000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7868000
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1762000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	278000
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90069000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77089000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50299000
CY2023	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	0
CY2022	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	0
CY2021	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	1000
CY2023	prok	Net Cash From Scs NetCashFromScs	0
CY2022	prok	Net Cash From Scs NetCashFromScs	108000
CY2021	prok	Net Cash From Scs NetCashFromScs	0
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	471604000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	175818000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34197000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1846000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5192000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-329983000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1738000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5191000
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	52000
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	32000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	30000
CY2023	prok	Costs Of Business Combination CostsOfBusinessCombination	37856000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	542503000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	35000000
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	9499000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	35000000
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0
CY2023	prok	Net Cash Contribution NetCashContribution	0
CY2022	prok	Net Cash Contribution NetCashContribution	6050000
CY2021	prok	Net Cash Contribution NetCashContribution	71500000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-9551000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	548521000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	71470000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-429603000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	469694000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15980000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	490252000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20558000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4578000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60649000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	490252000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20558000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2857000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1950000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	68000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2594000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1491000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2023	prok	Exchange Of Class B Ordinary Shares Amount ExchangeOfClassBOrdinarySharesAmount	9500000
CY2022	prok	Exchange Of Class B Ordinary Shares Amount ExchangeOfClassBOrdinarySharesAmount	0
CY2021	prok	Exchange Of Class B Ordinary Shares Amount ExchangeOfClassBOrdinarySharesAmount	0
CY2023	prok	Change In Redeemable Noncontrolling Interest For Equity Compensation And Equity Transactions ChangeInRedeemableNoncontrollingInterestForEquityCompensationAndEquityTransactions	2577000
CY2022	prok	Change In Redeemable Noncontrolling Interest For Equity Compensation And Equity Transactions ChangeInRedeemableNoncontrollingInterestForEquityCompensationAndEquityTransactions	5828000
CY2021	prok	Change In Redeemable Noncontrolling Interest For Equity Compensation And Equity Transactions ChangeInRedeemableNoncontrollingInterestForEquityCompensationAndEquityTransactions	0
CY2023	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-79000
CY2022	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	0
CY2023	prok	Equipment And Facility Expansion Included In Accounts Payable And Accrued Expenses EquipmentAndFacilityExpansionIncludedInAccountsPayableAndAccruedExpenses	218000
CY2022	prok	Equipment And Facility Expansion Included In Accounts Payable And Accrued Expenses EquipmentAndFacilityExpansionIncludedInAccountsPayableAndAccruedExpenses	51000
CY2021	prok	Equipment And Facility Expansion Included In Accounts Payable And Accrued Expenses EquipmentAndFacilityExpansionIncludedInAccountsPayableAndAccruedExpenses	1295000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1: Description of Business and Basis of Presentation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ProKidney Corp. (the “Company” or “ProKidney”) was originally incorporated as </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Social Capital Suvretta Holdings Corp. III (“SCS”). SCS was a blank check company incorporated as a Cayman Islands exempted company on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 25, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. SCS was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 18, 2022, SCS executed a definitive business combination agreement (the “Business Combination Agreement”), with ProKidney LP (“PKLP”), a limited partnership under the laws and regulations of Ireland. Pursuant to the terms of the Business Combination Agreement, PKLP became a subsidiary of SCS and was organized in an umbrella partnership corporation (“Up-C”) structure, which would provide potential future tax benefits for SCS when the equity holders ultimately exchanged their pass-through interests for Class A ordinary shares. The transaction closed (the “Closing”) on July 11, 2022 (the “Closing Date”). Upon consummation of the transaction, SCS changed its name to ProKidney Corp.</span></p><p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The business combination between SCS and PKLP (the “Business Combination”) resulted in gross proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">596,537,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. This amount reflected a contribution of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21,737,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of cash held in SCS’ trust account, net of redemptions, and a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">574,800,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> concurrent private placement of Class A ordinary shares of the combined company, priced at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (the “PIPE Placement”). Upon close, these proceeds were used to repay the outstanding balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">35,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> under PKLP’s two promissory note agreements with certain holders of its Class A Units (the “Promissory Notes”) and related accrued interest. Additionally, the proceeds were used to pay those expenses previously incurred by SCS related to the Business Combination of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21,029,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as well as advisory and placement fees of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29,389,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> incurred in connection with the PIPE Placement.</span></p><p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Business Combination was accounted for as a reverse recapitalization transaction between entities under common control, through which PKLP was considered the accounting acquiror and predecessor entity. The Business Combination was reflected as the equivalent of PKLP issuing stock for the net assets of SCS accompanied by a recapitalization with no goodwill or intangible assets recognized.</span></p><p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ProKidney Corp., through its operating subsidiaries, ProKidney, which is incorporated under the Cayman Islands Companies Act (as amended) as an exempted company (“ProKidney-KY”) and ProKidney LLC, a limited liability company under the laws of Delaware (“ProKidney-US”) is focused on the development of its Renal Autologous Cell Therapy (rilparencel), which has the potential to preserve kidney function in patients with chronic kidney disease or delay or eliminate the need for dialysis and organ transplantation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ProKidney Corp. is a holding company, and its principal asset is a controlling equity interest in PKLP and its wholly-owned operating subsidiaries ProKidney-KY and ProKidney-US. The Company has determined that PKLP is a variable-interest entity for accounting purposes and that ProKidney is the primary beneficiary of PKLP because (through its managing member interest in PKLP and the fact that the senior management of ProKidney is also the senior management of PKLP) it has the power and benefits to direct all of the activities of PKLP, which include those that most significantly impact PKLP’s economic performance. The Company has therefore consolidated PKLP’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Consolidated Financial Statements. As of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, various holders own non-voting interests in PKLP, representing a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">73.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% economic interest in PKLP, effectively restricting ProKidney’s interest to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of PKLP’s economic results, subject to increase in the future, should ProKidney purchase additional non-voting common units (“PKLP Units”) of PKLP, or should the holders of PKLP Units decide to exchange such units (together with shares of Class B ordinary shares) for Class A ordinary shares (or cash) pursuant to the Exchange Agreement (as defined in Note 6). The Company will not be required to provide financial or other support for PKLP. However, ProKidney will control its business and other activities through its ownership of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the shares in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ProKidney Corp. GP Limited (“New GP”), which is the managing member of PKLP. Nevertheless, because ProKidney will have no material assets other than its interests in PKLP and its subsidiaries, any financial difficulties at PKLP could result in ProKidney recognizing a loss.</span></p><p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All intercompany transactions and balances have been eliminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To facilitate comparison of information across periods, certain reclassifications have been made to prior period amounts to conform to the current period’s presentation.</span></p>
CY2023	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2021-02-25
CY2023	prok	Proceeds From Business Combination Gross ProceedsFromBusinessCombinationGross	596537000
CY2023	prok	Costs Paid With Proceeds For Spac CostsPaidWithProceedsForSpac	21029000
CY2023	prok	Advisory And Placement Fees AdvisoryAndPlacementFees	29389000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and equivalents are the primary financial instruments held by the Company that are potentially subject to concentrations of credit risk. The Company’s cash and equivalents are deposited in accounts at large financial institutions, and such amounts may exceed federally insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	prok	Accrued Compensation And Related Costs Current AccruedCompensationAndRelatedCostsCurrent	5237000
CY2022Q4	prok	Accrued Compensation And Related Costs Current AccruedCompensationAndRelatedCostsCurrent	3355000
CY2023Q4	prok	Accrued Severance Cost Current AccruedSeveranceCostCurrent	2283000
CY2022Q4	prok	Accrued Severance Cost Current AccruedSeveranceCostCurrent	0
CY2023Q4	prok	Accrued Clinical Study Related Costs Current AccruedClinicalStudyRelatedCostsCurrent	1658000
CY2022Q4	prok	Accrued Clinical Study Related Costs Current AccruedClinicalStudyRelatedCostsCurrent	1636000
CY2023Q4	prok	Accrued Facility Related Cost Current AccruedFacilityRelatedCostCurrent	693000
CY2022Q4	prok	Accrued Facility Related Cost Current AccruedFacilityRelatedCostCurrent	0
CY2023Q4	prok	Accrued Legal Expense Current AccruedLegalExpenseCurrent	1015000
CY2022Q4	prok	Accrued Legal Expense Current AccruedLegalExpenseCurrent	436000
CY2023Q4	prok	Accrued Manufacturing Improvement Costs Current AccruedManufacturingImprovementCostsCurrent	4365000
CY2022Q4	prok	Accrued Manufacturing Improvement Costs Current AccruedManufacturingImprovementCostsCurrent	678000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	878000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1210000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1536000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	21000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17665000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7336000
CY2023	prok	Estimatedusefullivesassetstabletextblock Estimatedusefullivesassetstabletextblock	<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The estimated useful lives are as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:58.9%;"></td> <td style="width:41.1%;"></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Buildings</span></p></td> <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"> <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer equipment and software</span></p></td> <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture and equipment</span></p></td> <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> years</span></p></td> </tr> <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;"> <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">remainder of lease term</span></span></p></td> </tr> </table>
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7642000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4708000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42143000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10708000
CY2023	us-gaap	Depreciation Depreciation	2956000
CY2022	us-gaap	Depreciation Depreciation	2448000
CY2021	us-gaap	Depreciation Depreciation	1452000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1073000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1073000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1073000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	860000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	213000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	213000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	215000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	214000
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	503000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	267000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	169000
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	310210000
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	0
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	310210000
CY2023Q4	prok	Available For Sale Securities Continuous Unrealized Loss Positions Less Than12 Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsLessThan12MonthsFairValue	78847000
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	48000
CY2023Q4	prok	Available For Sale Securities Continuous Unrealized Loss Positions12 Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositions12MonthsOrLongerFairValue	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2023Q4	prok	Available For Sale Securities Continuous Unrealized Loss Positions Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionsFairValue	78847000
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	48000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	5918000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	896000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	72000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	78000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-34000
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	5996000
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	896000
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	38000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5996000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	896000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2023	prok	Effective Income Tax Rate Reconciliation Change In Llc Flow Through Structure EffectiveIncomeTaxRateReconciliationChangeInLlcFlowThroughStructure	-0.173
CY2022	prok	Effective Income Tax Rate Reconciliation Change In Llc Flow Through Structure EffectiveIncomeTaxRateReconciliationChangeInLlcFlowThroughStructure	-0.184
CY2021	prok	Effective Income Tax Rate Reconciliation Change In Llc Flow Through Structure EffectiveIncomeTaxRateReconciliationChangeInLlcFlowThroughStructure	-0.214
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.013
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.008
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	0.018
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.022
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.024
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.073
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.014
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.013
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.046
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.006
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	1302000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses	678000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	0
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	227000
CY2023Q4	prok	Deferred Tax Assets Leases DeferredTaxAssetsLeases	34000
CY2022Q4	prok	Deferred Tax Assets Leases DeferredTaxAssetsLeases	10000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3163000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	637000
CY2023Q4	prok	Research And Experimental Costs Capitalized ResearchAndExperimentalCostsCapitalized	9556000
CY2022Q4	prok	Research And Experimental Costs Capitalized ResearchAndExperimentalCostsCapitalized	3504000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	294000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	0
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	32000
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	35000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14381000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5091000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12888000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3332000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1493000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1759000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	45000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1481000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1708000
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	12000
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	6000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1493000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1759000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12888000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3332000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1278000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	311000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	180000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	28000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	9000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	229000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	122000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	568000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	311000
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0
CY2023Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P12M
CY2021Q1	prok	Right Of Use Assets Operating And Finance Lease RightOfUseAssetsOperatingAndFinanceLease	1560000
CY2021Q1	prok	Operating And Finance Lease Liabilities Current OperatingAndFinanceLeaseLiabilitiesCurrent	1559000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1062000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	551000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	434000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	774000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4116000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2285000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	751000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	458000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3506000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1858000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4257000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2316000
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	147000
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	71000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	52000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	35000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	104000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	48000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	156000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	83000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1144000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	62000
CY2023Q4	prok	Lessee Operating Lease And Finance Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1206000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1247000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	32000
CY2023Q4	prok	Lessee Operating Lease And Finance Lease Liability Payments Due Year Two LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo	1279000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1326000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	22000
CY2023Q4	prok	Lessee Operating Lease And Finance Lease Liability Payments Due Year Three LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree	1348000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1002000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	22000
CY2023Q4	prok	Lessee Operating Lease And Finance Lease Liability Payments Due Year Four LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour	1024000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	608000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	22000
CY2023Q4	prok	Lessee Operating Lease And Finance Lease Liability Payments Due Year Five LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive	630000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	49000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	22000
CY2023Q4	prok	Lessee Operating Lease And Finance Lease Liability Payments Due After Year Five LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive	71000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5376000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	182000
CY2023Q4	prok	Lessee Operating Lease And Finance Lease Liability Payments Due LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue	5558000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1119000
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	26000
CY2023Q4	prok	Lessee Operating Lease And Finance Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount	-1145000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4257000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	156000
CY2023Q4	prok	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	4413000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.102
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.065
CY2023Q1	prok	Shares Unlocked Percentage SharesUnlockedPercentage	0.50
CY2023	prok	Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Impact Of Restricted Common Units Vesting ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesImpactOfRestrictedCommonUnitsVesting	-4795000
	prok	Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Impact Of Restricted Common Units Vesting ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesImpactOfRestrictedCommonUnitsVesting	-321000
CY2023	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet	-42758000
	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Change Due To Net Income Attributable To Parent And Effects Of Changes Net ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet	-8571000
CY2023	us-gaap	Profit Loss ProfitLoss	-135447000
	us-gaap	Profit Loss ProfitLoss	-54503000
CY2023	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable	-99979000
	us-gaap	Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable	-40103000
CY2023	prok	Earnout Shares EarnoutShares	17500000
CY2022	prok	Earnout Shares EarnoutShares	17500000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14680109
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9504715
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.815
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.84
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.82
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.85
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.035
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.047
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.037
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.044
CY2023Q4	prok	Expected Dividend Yield ExpectedDividendYield	0
CY2022Q4	prok	Expected Dividend Yield ExpectedDividendYield	0
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2023	prok	Profits Interests Granted ProfitsInterestsGranted	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20749000000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6984000000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	3011000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30846000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74469000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	699000

Files In Submission

Name	View Source	Status
0000950170-24-034946-index-headers.html	Edgar Link	pending
0000950170-24-034946-index.html	Edgar Link	pending
0000950170-24-034946.txt	Edgar Link	pending
0000950170-24-034946-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img229617485_0.jpg	Edgar Link	pending
img229617485_1.jpg	Edgar Link	pending
img229617485_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
prok-20231231.htm	Edgar Link	pending
prok-20231231.xsd	Edgar Link	pending
prok-ex10_5.htm	Edgar Link	pending
prok-ex21_1.htm	Edgar Link	pending
prok-ex23_1.htm	Edgar Link	pending
prok-ex31_1.htm	Edgar Link	pending
prok-ex31_2.htm	Edgar Link	pending
prok-ex32_1.htm	Edgar Link	pending
prok-ex32_2.htm	Edgar Link	pending
prok-ex4_1.htm	Edgar Link	pending
prok-ex97.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
prok-20231231_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PROK
PROKIDNEY CORP. Stock $prok

2023 Q4 Form 10-K Financial Statement

#000095017024034946 Filed on March 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PROK PROKIDNEY CORP. Stock $prok

2023 Q4 Form 10-K Financial Statement

#000095017024034946 Filed on March 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PROK
PROKIDNEY CORP. Stock $prok